Senti Bio reports Q1 EPS (14c), consensus (36c)

“We entered 2026 with a clear focus on advancing SENTI-202 and extending our operational runway while positioning the company for its next phase of clinical development,” said Timothy Lu, Chief Executive Officer and Co-Founder of Senti Bio (SNTI). “Since the start of the year, we have made meaningful progress across each of these priorities, including a positive regulatory engagement with the FDA on SENTI-202 – a Regenerative Medicine Advanced Therapy designated product – regarding the study design for the planned pivotal trial, execution of a strategic financing agreement that could provide up to $40 million in capital, and continued reductions in operating expenses and cash burn.”